The amino acid transporter PAT1 is typically expressed on the lysosome and plasma membranes in various human tissues. Glycosylation has been shown to be critical for the cell surface expression of PAT1, but not for its stability, in Xenopus oocytes. Here, we report that the glycosylation-deficient mutant of PAT1 (PAT1 3NQ ) is unstable and is degraded mainly via the endoplasmic reticulum-associated degradation pathway in HEK293 cells. Interestingly, PAT1
The amino acid transporter PAT1 is typically expressed on the lysosome and plasma membranes in various human tissues. Glycosylation has been shown to be critical for the cell surface expression of PAT1, but not for its stability, in Xenopus oocytes. Here, we report that the glycosylation-deficient mutant of PAT1 (PAT1 3NQ ) is unstable and is degraded mainly via the endoplasmic reticulum-associated degradation pathway in HEK293 cells. Interestingly, PAT1
3NQ binds preferentially to the plasma membrane rather than to the lysosome. Consistent with this altered distribution, overexpression of PAT1 3NQ fails to inhibit the mechanistic target of rapamycin complex 1 (mTORC1). Our data suggest that glycosylation affects the stability and localization of PAT1 in HEK293 cells and the subcellular distribution of PAT1 is a factor affecting mTORC1 activity.
Keywords: glycosylation; lysosome; mTORC1; PAT1; stability The proton-coupled amino acid transporter PAT1 belongs to the solute carrier protein family 36 (SLC36), which also contains PAT2-4. A well-characterized function of PAT1 is to transport amino acids, together with H + , across the cellular membrane into the cytosol [1] . There is ample evidence that the substrates of PAT1 are broad, and not only include amino acids [2] [3] [4] [5] [6] but also imino acids [7] , fatty acids [8] , amino acid-related compounds and drugs, among other factors [9] [10] [11] [12] [13] . Thus, PAT1 has been extensively investigated in both physiological and pharmacological studies [14] . PAT1 is wildly expressed and displays diverse subcellular localizations. It is typically located on the cell surface and lysosomes of neurons [2, 4, 5] and the intestinal epithelia [5, 7] . It is also colocalized with markers of various membrane compartments, including axons and secretory vesicles in rat neuronal cells [4] and in podosomes in both human macrophages and mouse NIH3T3 cells [15] . In rat smooth muscle cells, PAT1 is even expressed in the nucleus [16] . These observations suggest that PAT1 is a multifunctional protein and its intracellular trafficking pathways must be tightly controlled. Recently, several studies have uncovered an important role of PAT1 in the mechanistic target of rapamycin complex 1 (mTORC1) signalling pathway, which may link PAT1 with growth control and even certain pathological conditions [17] [18] [19] [20] [21] .
The multiprotein complex mTORC1 is the central machinery for cells to sense the amino acid supply and adjust cell metabolism to the nutrient status. Deregulated mTORC1 has been observed in a wide range of Abbreviations 4EBP1, eukaryotic translation initiation factor 4E-binding protein 1; Baf A1, bafilomycin A1; BFA, brefeldin A; CHX, cycloheximide; Eer I, eeyarestatin I; ERAD, endoplasmic reticulum-associated degradation; LAMP1, lysosome-associated membrane protein 1; mTORC1, the mechanistic target of rapamycin complex 1; PAT1, proton-coupled amino acid transporter 1; pS6K1, phosphor-ribosomal protein S6 kinase 1; S6K1, ribosomal protein S6 kinase 1; TfR, transferrin receptor. diseases, including diabetes, cancer and neurodegenerative disorders [22] . During recent years, an important discovery in the mTORC1 field was the identification of lysosome as a key site for mTORC1 activation. It is becoming increasingly clear that lysosome plays at least two roles in mTORC1 activation. First, the luminal amino acid pool is a direct signal to activate mTORC1; second, the lysosome surface anchors some critical factors to transduce the amino acid signal to mTORC1 [23, 24] .
PAT1 has been proposed to regulate mTORC1 through two different mechanisms. In one mechanism, PAT1 was found to activate mTORC1 through direct interactions with the Rag proteins (components of the amino acids signal-sensing machinery) and was suspected to participate in the signal transduction process [18] . In the second mechanism, PAT1 plays a more upstream role by reducing the amino acid levels within the lysosome and hence inhibits mTORC1 [19, 20] . Currently, how PAT1 can either activate or inhibit mTORC1 is not fully understood yet [23] .
Biochemical studies have revealed that PAT1 protein can undergo two types of post-translational modifications, including glycosylation [25] and the formation of an internal disulphide bond [26] . Using Xenopus oocyte as an expression system, Dorn et al. found that human PAT1 protein was mainly glycosylated on three asparagine residues in the extracellular regions (N174, 183, 470). Replacing all three loci with glutamine (N174/ 183/470Q, referred to as 3NQ hereafter) abolished most of the glycosylation modifications and had a minimal impact on protein conformation [25] . The authors further demonstrated that the protein stability and transport activity of the nonglycosylated PAT1 (PAT1 3NQ ) were similar with those of the wild-type PAT1. However, immunostaining studies revealed that PAT1 3NQ did not attach to the plasma membrane. On the bases of these results, the authors proposed that the glycosylation modification was important to target PAT1 onto the cell surface, but did not protect it from degradation [25] . Unfortunately, the authors did not further investigate where PAT1 3NQ proteins were localized.
We were very interested in these findings [25] . If PAT1 3NQ was not expressed on the cell surface, we suspected that it might be relocated to the lysosome, which is a main intracellular compartment to anchor PAT1 in many cell types. If this hypothesis was correct, the mislocalized PAT1 (3NQ) could be an ideal system to test the role of the lysosome-anchored PAT1 on mTORC1 activity. In the current work, we analysed the glycosylation-deficient PAT1 fusion protein (EGFP-PAT1 3NQ ) in the human embryonic kidney 293 cells (HEK293). To our surprise, overexpression of EGFP-PAT1 3NQ did not inhibit mTORC1. In contrast, mTORC1 activity was even slightly increased. To account for this result, we examined the cellular properties of EGFP-PAT1 3NQ in human cells. We found that glycosylation was critical to stabilize PAT1 protein in both HEK293 and HeLa cells. In addition, EGFP-PAT1 3NQ proteins appeared to be degraded mainly via the endoplasmic reticulum-associated degradation (ERAD) pathway. We also demonstrate that compared with the wild-type protein, the EGFP-PAT1 3NQ preferentially bond with the cell surface rather than the lysosome. This altered distribution may account for the increased mTORC1 activity observed in the EGFP-PAT1 3NQ -expressing cells. Taken together, our data suggest that glycosylation regulates the stability and subcellular localizations of PAT1, thereby affecting mTORC1 activity in specific human cells.
Materials and methods
Cell culture, plasmid construction and stable cell line selection Cells were grown in complete medium: Dulbecco's modified Eagle's medium supplemented with 8% fetal bovine serum, 4 mM L-glutamine, 4500 mgÁL À1 glucose and sodium pyruvate, at 37°C and 5% CO 2 . The EGFP-PAT1 3NQ constructs were derived from EGFP-PAT1 [20] by replacing the three asparagine residues with glutamine [25] through PCR. Stable cell lines were obtained by selection with G418 (Invitrogen, Carlsbad, CA, USA).
Antibodies and reagents
The following antibodies were used: mouse monoclonal lysosome-associated membrane protein 1 (LAMP1; H4A3) and GFP (12A6 and 8H11) from Developmental Studies Hybridoma Bank; mouse monoclonal beta-actin (KM9001T) from Sungene Biotech (Tianjin, China); rabbit polyclonal Calnexin (22595) from Abcam (Cambridge, UK); pS6K1 (T389, #9205), S6K1 (#9202), p4EBP1 (D9G1Q) and 4EBP1 (53H11) from Cell Signalling Technology (Danvers, MA, USA); mouse monoclonal pancadherin (CH-19) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); rabbit polyclonal to GFP (A11122) and the fluorescent secondary antibodies from Life Technologies (Carlsbad, CA, USA); Bafilomycin A1 (Baf A1; 54645), MG132 (2194), Brefeldin A (BFA; 9972) and Streptavidin (Sepharose Bead Conjugate, 3419) from Cell Signalling Technology; Eeyarestatin I (Eer I; SC-358130) from Santa Cruz Biotechnology; Sulfo-NHS-LC-Biotin (2103) from ProteoChem (Denver, CO, USA).
Quantitative reverse-transcription PCR
Total RNA was extracted using TRIzol as described before [20] . The quantitative reverse-transcription PCR (qRT-PCR) reactions were performed using the QuantStudio TM 12K Flex Real-Time PCR System (Life Technologies). All data were normalized to actin gene in the corresponding sample. qPCR primer sequences were as follows: GFP-F: GAAGAACGG CATCAAGGTG, GFP-R: CGGACTGGGTGCTCAGG TAG; actin-F: GCCCTGAGGCACTCTTCCA, actin-R: TGTTGGCGTACAGGTCTTTGC.
Cell lysis and western blotting analyses
Cells were washed once in ice-cold 19 PBS, harvested and lysed in RIPA lysis buffer (Nanjing KeyGen Biotech, Nanjing, China) containing 25 mM Tris/HCl pH 7.6, 150 mM NaCl, 0.5 mM PMSF, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, protease and phosphatase inhibitors. The lysates were cleared by centrifugation at 18 500 g for 15 min at 4°C. Protein concentration of the supernatant was measured by bicinchoninic acid assay. The supernatant was fixed with SDS loading buffer and boiled for 5 min. To prepare the unboiled samples (Fig. S1 ), the supernatant was fixed with SDS loading buffer followed by keeping at 4°C overnight. For western blotting, the samples were separated by SDS/PAGE and transferred onto poly(vinylidene difluoride) (PVDF). The PVDF membranes were blocked in 5% nonfat milk, incubated with primary antibodies and subsequently, with HRP-conjugated secondary antibodies; immunoreactivity was detected using ECL and chemiluminescence reagents (Bio-Rad, Hercules, CA, USA).
Lysosome purification and cell surface biotinylation
Lysosomes were isolated using a Lysosome Isolation Kit (LYSISO1; Sigma-Aldrich, St. Louis, MO, USA) with certain modifications. Briefly, cells were grown on the 90 mm dish (three dishes) up to 80% confluence and then collected by centrifugation at 600 g for 5 min. The following steps were carried out on ice. The cells were resuspended in 200 lL extraction buffer and homogenized with five gentle strokes in a 2 mL Dounce glass tissue grinder. After centrifugation at 1000 g for 10 min, the supernatant was collected, and the pellet was homogenized for another four rounds. Supernatants from all homogenizations were then collected (~1 mL) and centrifuged at 20 000 g for 20 min. The pellet was resuspended in 25 lL of RIPA lysis buffer to yield the lysosome fraction.
Biotinylation of membrane proteins were essentially performed as previously described [27] . Cells grown on 90 mm dish (three dishes) were washed three times with ice-cold PBS (+) (containing 0.1 mM CaCl 2 and 0.1 mM MgCl 2 , pH 7.4) and incubated with 500 lL Sulfo-NHS-LC-biotin (0.5 mgÁmL
À1
) for 30 min on ice. The cells were washed twice with ice-cold PBS (+) containing 100 mM glycine and 0.3% (w/v) BSA, twice with PBS (+). The cells were then lysed in 500 lL of the lysis buffer: 50 mM HEPES-KOH, pH 7.2, 150 mM NaCl, 1% Triton X-100, and protease and phosphatase inhibitors (Roche, Mannheim, Germany). The lysates were centrifuged at 15 000 g for 10 min at 4°C, the supernatant was incubated with streptavidin-agarose beads overnight at 4°C. The beads were then washed three times with the lysis buffer, twice with a high-salt wash buffer (50 mM Tris/HCl, pH 7.5, 500 mM NaCl and 1% Triton X-100), and once with 50 mM Tris/HCl, pH 7.5. The beads were then lysed with 20 lL of the lysis buffer plus 30 lL of the SDS loading buffer and processed for western blotting analyses.
Results

Overexpression of EGFP-PAT1 3NQ does not inhibit mTORC1 in HEK293 cells
Human PAT1 is predicated to be a multitransmembrane protein with six extracellular domains (Fig. 1A ) [28] . In a previous study [20] , we generated stable 293 cell lines expressing EGFP-PAT1, which encodes a human PAT1 fusion protein with an N-terminal EGFP tag. Using these cells as a model, we found that some EGFP-PAT1 proteins were present on the lysosome and that overexpression of EGFP-PAT1 decreased mTORC1 activity [20] . Similar results have been reported by other studies through checking either the endogenous PAT1 (for the localization assay) or chimeric PAT1 fused with different tags [17] [18] [19] . This suggests that the EGFP tag may have little effect on the conformation and functions of PAT1 protein.
We followed a previous finding [25] and modified the EGFP-PAT1 transgene by introducing triple point mutations on the three N-glycosylation sites (EGFP-PAT1 3NQ , Fig. 1A ). Next, we transfected the EGFP-PAT1 3NQ plasmid into HEK293 cells and generated several stable cell lines expressing this nonglycosylated form of PAT1. Using a mouse monoclonal anti-GFP antibody, we examined the expression of EGFP-PAT1 3NQ and EGFP-PAT1 through western blotting analysis and consistently detected two strong protein bands: one band corresponded to EGFP-tagged PAT1 fusion proteins (~80 kDa) and the other band represented their aggregated forms (> 120 kDa, Fig. 1B) . The aggregates were most likely formed during the sample preparation via strong hydrophobic interactions under boiling conditions (Fig. S1 ) [26] . Consistent with the previous observation, monomeric EGFP-PAT1 3NQ migrated slightly faster than EGFP-PAT1 (Fig. 1B) , which serves as an indicator of the nonglycosylated state of EGFP-PAT1 3NQ [25] . Next, we investigated the effect of EGFP-PAT1 3NQ on mTORC1 activity. We analysed three cell types, including control HEK293 cells, and several stable cells expressing EGFP-PAT1 or EGFP-PAT1 3NQ . The mTORC1 activities were examined by three markers, including the phosphorylated forms of ribosomal S6 kinase 1 (T389, pS6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (S65, p4EBP1), and the mobility shift extent of total 4EBP1 [17] [18] [19] [20] 29] . Under amino acid starvation environment, the mTORC1 activities were significantly decreased in all of the cells, as revealed by reduced pS6K1 and p4EBP1, and the fast migrations of total 4EBP1 bands (Fig. 1C, upper panel) . Once the starved cells were restimulated with complete medium (amino acids replenishment) for 10 min, all the stable cell lines expressing EGFP-PAT1 exhibited lower mTORC1 activities than the control cells (Fig. 1C, lower panel) . This result has been attributed to the reduced amino acids pool in the lysosome, which was caused by the excessive lysosomeanchored PAT1 [19, 20] . Surprisingly, we found that mTORC1 activities were either unchanged or modestly increased in three different cell lines stably expressing the EGFP-PAT1 3NQ (Fig. 1C,D) . Because PAT1 3NQ was not expressed on the cell surface of Xenopus oocytes [25] , we had speculated that it might translocate to the lysosome. Then, overexpression of PAT1 3NQ , which exhibited normal amino acids transport activity [25] , should promote the efflux of lysosomal amino acids and suppress mTORC1 even more strongly than wild-type PAT1. This unexpected result shown in Fig. 1C promoted us to re-examine the cellular properties of EGFP-PAT1 3NQ , including its expression level and subcellular distribution in HEK293 cells.
Glycosylation is important to stabilize PAT1 protein
We noticed in the western blotting data that the EGFP-PAT1 3NQ expression level was low compared with EGFP-PAT1 (Fig. 1B) . One possibility is that the EGFP-PAT1 3NQ proteins were rapidly degraded. Indeed, glycosylation is a common mechanism to prevent the degradation of a number of membrane proteins [30] . However, previous study has shown that PAT1 was unlikely protected by the glycosylation modification, because the protein levels of PAT1 3NQ (HA-PAT1 3NQ ) and the wild-type (HA-PAT1) were similar when expressed in Xenopus oocytes [25] .
To examine the role of glycosylation on the stability of PAT1 protein, we carefully analysed the expressions of EGFP-PAT1 or EGFP-PAT1 3NQ in several independent cell lines using western blotting. On the basis of at least three repeated experiments, we found that the protein levels of EGFP-PAT1 3NQ were lower than those of the EGFP-PAT1 (Fig. 2A) . This result can be explained by the poor stability of the EGFP-PAT1 3NQ transcript, which has six sites of nucleotide substitution. Then we measured the mRNA levels of the transgenes by qRT-PCR and ruled out this possibility (Fig. 2B, e. g. compare EGFP-PAT1 #9 with EGFP-PAT1 3NQ #3). In addition, the protein translation rates should be the same because both transgenes were constructed in the pEGFP-C1 vector. Taken together, these results suggest that EGFP-PAT1 3NQ is degraded more rapidly than wild-type EGFP-PAT1 in HEK293 cells.
To investigate whether glycosylation also affects PAT1 stability in other human cells, we transiently transfected HeLa cells with the EGFP-PAT1 or EGFP-PAT1 3NQ transgene. Twenty-four hours after the transfection, we found that the protein levels of EGFP-PAT1 3NQ were much lower than those of EGFP-PAT1 in three independent experiments. This finding suggests that EGFP-PAT1 3NQ is unstable in HeLa cells (Fig. 2C) . We suspect that some proteinases, which can recognize and digest PAT1 in HEK293 and HeLa cells, might be missing in Xenopus oocytes.
We performed another experiment to measure protein stability. We incubated the stable HEK293 cells expressing EGFP-PAT1 or EGFP-PAT1 3NQ with cycloheximide (CHX), which is a chemical that inhibits protein translation, and then examined the abundance of the EGFP-PAT1 and EGFP-PAT1 3NQ at different time points. We found that both proteins were fairly stable following the CHX treatment for as long as 8 h (relative to beta-actin, Fig. 2D ). More importantly, we did not observe clear differences on the degradation rates between the two proteins (Fig. 2D ). This implies that the degradation of EGFP-PAT1 3NQ should be processed during or immediately after protein synthesis in the ER. This hypothesis is supported by the following proteolysis inhibition experiments.
PAT1 3NQ is degraded mainly via the ERAD pathway
To investigate where the turnover of EGFP-PAT1 3NQ occurs, we fed cells inhibitors of various proteolysis systems and analysed the abilities of these inhibitors to preserve PAT1 proteins against degradation (Fig. 3) . Baf A1 inhibits the lysosomal proteinases through reducing the luminal proton levels [31] . We found that incubation of Baf A1 increased the protein level of the transferrin receptor (TfR) [32] , while the treatment had little effect to stabilize EGFP-PAT1 or EGFP-PAT1 3NQ (Fig. 3) . This finding indicates that the lysosome is unlikely a major place for the turnover of PAT1 proteins. In contrast, the specific proteasome inhibitor MG132 [33] suppressed the degradations of both EGFP-PAT1 and EGFP-PAT1 3NQ , and with a better efficiency on EGFP-PAT1 3NQ . Thus, the proteasome is a place to degrade both EGFP-PAT1 and EGFP-PAT1 3NQ . Interestingly, we found that the ERAD inhibitor Eer I [34] was more potent than MG132 in preserving EGFP-PAT1 3NQ proteins. ERAD is a cellular quality control system to monitor newly synthesized polypeptides. Nascent proteins with incorrect conformations and modifications will be recognized in the ER lumen and are delivered to the proteasomes inside the cytosol for degradation [35] . Based on the above results, we propose that the majority of EGFP-PAT1 3NQ degradation is initiated in the ER and processed in the proteasomes. This also explains why the degradation of PAT1 3NQ was not significant when the protein translation process was suppressed by CHX (Fig. 2D) . Consistent with this conclusion, we found that BFA, which can prevent the transport of membrane vesicles from the ER to the Golgi apparatus and therefore retains the proteins within the ER [36] , promoted the degradation of EGFP-PAT1 3NQ (Fig. 3, bottom) . Fig. 2A ). Cells were starved and replenished with amino acids, which is the same treatment in the experiments to analyse the mTORC1 activity (Fig. 1C) . After that, we isolated the lysosomes by cell fractionation and examined the abundance of lysosome-associated proteins using western blotting analyses (see Methods section). We found that both EGFP-PAT1 and EGFP-PAT1 3NQ were expressed on the lysosomes (Fig. 4A, left) . However, quantification analysis revealed that EGFP-PAT1 3NQ displayed a reduced affinity with the lysosome compared with EGFP-PAT1 (Fig. 4A, right) . Because inhibition of the lysosomal functions did not increase the EGFP-PAT1 3NQ levels (Fig. 3A) , we propose that inefficient delivery, rather than rapid protein degradation, accounts for the poor lysosomal localization of EGFP-PAT1
3NQ . Thus, glycosylation may play a role in assisting the transport of PAT1 to the lysosome.
PAT1
3NQ is expressed on the cell surface As PAT1 3NQ was poorly localized on the lysosome, we wonder if it was relocated to the cell surface. To investigate this, we labelled the proteins on the plasma membrane with biotin and examined the biotinylated proteins using western blotting. Interestingly, we detected a considerable level of cell surface-anchored EGFP-PAT1 3NQ (Fig. 4B, left) . After normalization with pan-cadherin, which serves as a cell surface marker, we found that EGFP-PAT1 3NQ showed an even higher affinity with the cell surface than EGFP-PAT1 (Fig. 4B, right) . These results suggest that PAT1 3NQ can be expressed on the cell surface of HEK293 cells, where it is more stable than the wild-type protein.
Discussion
The initial aim of this work was to investigate the effect of PAT1 3NQ on mTORC1 activity in a human system. Unexpectedly, we found that overexpression of PAT1 3NQ did not inhibit mTORC1 in HEK293 cells. This suggests that EGFP-PAT1 3NQ and EGFP-PAT1 have different effect on mTORC1 activity. Then, we examined the cellular properties of EGFP-PAT1 Firstly, we showed that glycosylation was important to protect PAT1 from degradation in both HEK293 and HeLa cells; and the turnover of EGFP-PAT1 3NQ was mainly mediated via the ERAD pathway. Secondly, we found that once EGFP-PAT1 3NQ escaped from the ERAD, it could be expressed on both the lysosome and the cell surface. We further demonstrated that EGFP-PAT1 3NQ tended to bind to the cell surface rather than the lysosome. Based on these results, we propose that glycosylation affects the stability and subcellular distribution of PAT1 at least in certain human cells. Although some of our data differ from those reported in a previous work [25] , we believe that the discrepancies are most likely caused by the different model systems used in these studies.
PAT1 is expressed in both cell surface and the lysosome in multiple cell types. However, there are few studies to address how PAT1 proteins are distributed in these two locations. Here, we provide evidence that glycosylation modulates the distribution of PAT1 on the cell surface and the lysosome. From the transGolgi network (TGN), the membrane proteins can travel through two pathways to the lysosome. In the direct pathway, they are sorted into the membrane vesicles that will gradually fuse with the lysosome. In the indirect pathway, they are initially delivered to the plasma membrane and subsequently move into the cell through endocytosis [37, 38] . The finding that EGFP-PAT1 3NQ preferentially bond with the cell surface suggests glycosylation may have a limited effect on the secretion of PAT1 from the TGN to the plasma membrane. Instead, glycosylation may play a role to drive PAT1 into the direct transport pathway to the lysosome, promote the invagination of PAT1 from the cell surface, or both. This explains why in the absence of glycosylation, the PAT1 3NQ was accumulated on the cell surface and could not be efficiently delivered to the lysosome.
Recent studies have revealed an important role of PAT1 during the regulation of mTORC1. Suppression of PAT1 has been shown to inhibit mTORC1 in different human cell types and the Drosophila animal model [18, 20] . However, the precise mechanism underlying the control of mTORC1 by PAT1 remains elusive. It has been found that in PAT1-overexpressing HEK293 cells, mTORC1 activity was either increased or decreased following amino acid starvation and replenishment treatment [18] [19] [20] . In a previous work, we proposed an explanation for these controversial observations based on the finding that the lysosomal localization of PAT1 is dynamic and is regulated by amino acid supply [20] . Upon amino acids starvation, PAT1 was accumulated on the lysosome to recycle the nutrient storage and suppress mTORC1. Once amino acids were supplemented, the lysosome-associated PAT1 was decreased. We found that mTORC1 activity was sensitive to the duration of amino acid replenishment. For short periods of amino acid incubation (< 10 min), the lysosome was still anchored with many PAT1 proteins, and the mTORC1 activity was low [19, 20] ; for a longer time period (> 30 min), the level of PAT1 on the lysosome was reduced and the mTORC1 activity was recovered to the control levels [18] . These results support that the subcellular distribution of PAT1 is an important factor affecting mTORC1 activity. According to our provisional model, the lysosome-associated PAT1 inhibits mTORC1; while on the cell surface, it promotes mTORC1 through the bulk uptake of amino acids into the cell. Consistent with this, we found that the mTORC1 activity was increased in the cells overexpressing the mislocalized EGFP-PAT1 3NQ (Fig. 1C,D) .
